An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-017
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Nov 2017 Health-related quality of life (HRQoL) and symptom assessments, published in the Journal of Thoracic Oncology
    • 18 Oct 2017 Results of a subgroup analyses in patients with baseline liver metastases from two phase III trials (CheckMate 017 and 05; n=193) presented at the 18th World Conference on Lung Cancer
    • 12 Oct 2017 Results of pooled analysis of CheckMate 017 and CheckMate 057 assessing two year efficacy outcomes published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top